nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Epoprostenol—Sweating—Vincristine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Epoprostenol—Nausea—Mechlorethamine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Epoprostenol—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Epoprostenol—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Epoprostenol—Haemoglobin—Carmustine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Epoprostenol—Urticaria—Teniposide—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Epoprostenol—Haemorrhage—Carmustine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Epoprostenol—Abdominal pain—Teniposide—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Epoprostenol—Body temperature increased—Teniposide—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Epoprostenol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Epoprostenol—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Epoprostenol—Sweating—Mitoxantrone—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Epoprostenol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Epoprostenol—Haematuria—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Epoprostenol—Oedema peripheral—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Epoprostenol—Connective tissue disorder—Carmustine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Epoprostenol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Epoprostenol—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Epoprostenol—Decreased appetite—Fludarabine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Epoprostenol—Fatigue—Fludarabine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Epoprostenol—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Epoprostenol—Constipation—Fludarabine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Epoprostenol—Pain—Fludarabine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Epoprostenol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Epoprostenol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Epoprostenol—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Epoprostenol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Epoprostenol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Epoprostenol—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Epoprostenol—Flushing—Carmustine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Epoprostenol—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Epoprostenol—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Epoprostenol—Anaemia—Bleomycin—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Epoprostenol—Asthenia—Teniposide—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Epoprostenol—Pruritus—Teniposide—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Epoprostenol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Epoprostenol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Epoprostenol—Mental disorder—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Epoprostenol—Cough—Bleomycin—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Epoprostenol—Angiopathy—Vincristine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Epoprostenol—Diarrhoea—Teniposide—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Epoprostenol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Epoprostenol—Chest pain—Bleomycin—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Epoprostenol—Myalgia—Bleomycin—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Epoprostenol—Back pain—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Epoprostenol—Mental disorder—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Epoprostenol—Chills—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Epoprostenol—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Epoprostenol—Confusional state—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Epoprostenol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Epoprostenol—Tremor—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Epoprostenol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Epoprostenol—Oedema—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Epoprostenol—Infection—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Epoprostenol—Anaemia—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Epoprostenol—Back pain—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Epoprostenol—Vomiting—Teniposide—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Epoprostenol—Sepsis—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Epoprostenol—Agitation—Carmustine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Epoprostenol—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Epoprostenol—Asthenia—Fludarabine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Epoprostenol—Rash—Teniposide—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Epoprostenol—Dermatitis—Teniposide—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Epoprostenol—Headache—Teniposide—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Epoprostenol—Pruritus—Fludarabine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Epoprostenol—Back pain—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Epoprostenol—Anorexia—Bleomycin—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Epoprostenol—Anaemia—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Epoprostenol—Agitation—Vincristine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Epoprostenol—Hypotension—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Epoprostenol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Epoprostenol—Nausea—Teniposide—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Epoprostenol—Anaemia—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Epoprostenol—Hepatic failure—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Epoprostenol—Chest pain—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Epoprostenol—Myalgia—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Epoprostenol—Anxiety—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Epoprostenol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Epoprostenol—Dyspnoea—Bleomycin—lymphatic system cancer	0.002	0.002	CcSEcCtD
Epoprostenol—Confusional state—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Epoprostenol—Oedema—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Epoprostenol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Epoprostenol—Myalgia—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Epoprostenol—Cough—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Epoprostenol—Infection—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Epoprostenol—Vomiting—Fludarabine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Epoprostenol—Rash—Fludarabine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Epoprostenol—Dermatitis—Fludarabine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Epoprostenol—Pain—Bleomycin—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Epoprostenol—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Epoprostenol—Headache—Fludarabine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Epoprostenol—Tachycardia—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Epoprostenol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Epoprostenol—Chest pain—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Epoprostenol—Myalgia—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Epoprostenol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Epoprostenol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Epoprostenol—Oedema—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Epoprostenol—Anorexia—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Epoprostenol—Infection—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Epoprostenol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Epoprostenol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Epoprostenol—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Epoprostenol—Hypotension—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Epoprostenol—Oedema—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Epoprostenol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Epoprostenol—Nausea—Fludarabine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Epoprostenol—Infection—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Epoprostenol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Epoprostenol—Shock—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Epoprostenol—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Epoprostenol—Urticaria—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Epoprostenol—Anorexia—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Epoprostenol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Epoprostenol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Epoprostenol—Insomnia—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Epoprostenol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Epoprostenol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Epoprostenol—Paraesthesia—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Epoprostenol—Hypotension—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Epoprostenol—Dyspnoea—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Epoprostenol—Somnolence—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Epoprostenol—Anorexia—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Epoprostenol—Decreased appetite—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Epoprostenol—Hypotension—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Epoprostenol—Insomnia—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Epoprostenol—Paraesthesia—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Epoprostenol—Constipation—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Epoprostenol—Pain—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Epoprostenol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Epoprostenol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Epoprostenol—Decreased appetite—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Epoprostenol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Epoprostenol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Epoprostenol—Fatigue—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Epoprostenol—Asthenia—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Epoprostenol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Epoprostenol—Pain—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Epoprostenol—Constipation—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Epoprostenol—Pruritus—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Epoprostenol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Epoprostenol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Epoprostenol—Constipation—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Epoprostenol—Pain—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Epoprostenol—Body temperature increased—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Epoprostenol—Abdominal pain—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Epoprostenol—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Epoprostenol—Pancytopenia—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Epoprostenol—Body temperature increased—Vincristine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Epoprostenol—Abdominal pain—Vincristine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Epoprostenol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Epoprostenol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Epoprostenol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Epoprostenol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Epoprostenol—Vomiting—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Epoprostenol—Depression—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Epoprostenol—Rash—Bleomycin—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Epoprostenol—Dermatitis—Bleomycin—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Epoprostenol—Asthenia—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Epoprostenol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Epoprostenol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Epoprostenol—Asthenia—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Epoprostenol—Diarrhoea—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Epoprostenol—Nausea—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Epoprostenol—Asthenia—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Epoprostenol—Dizziness—Carmustine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Epoprostenol—Diarrhoea—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Epoprostenol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Epoprostenol—Vomiting—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Epoprostenol—Dizziness—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Epoprostenol—Rash—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Epoprostenol—Dermatitis—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Epoprostenol—Headache—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Epoprostenol—Vomiting—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Epoprostenol—Rash—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Epoprostenol—Dermatitis—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Epoprostenol—Headache—Vincristine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Epoprostenol—Nausea—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Epoprostenol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Epoprostenol—Rash—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Epoprostenol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Epoprostenol—Chills—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Epoprostenol—Headache—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Epoprostenol—Nausea—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Epoprostenol—Nausea—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Epoprostenol—Cough—Methotrexate—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000938	0.000938	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Epoprostenol—Infection—Methotrexate—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000886	0.000886	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—lymphatic system cancer	0.000863	0.000863	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—lymphatic system cancer	0.000846	0.000846	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000825	0.000825	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000807	0.000807	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000797	0.000797	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000781	0.000781	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—lymphatic system cancer	0.00078	0.00078	CcSEcCtD
Epoprostenol—Pain—Methotrexate—lymphatic system cancer	0.000774	0.000774	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00074	0.00074	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—lymphatic system cancer	0.000719	0.000719	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—lymphatic system cancer	0.000716	0.000716	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000716	0.000716	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000667	0.000667	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—lymphatic system cancer	0.00064	0.00064	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000619	0.000619	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—lymphatic system cancer	0.000599	0.000599	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Epoprostenol—Rash—Methotrexate—lymphatic system cancer	0.000571	0.000571	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—lymphatic system cancer	0.00057	0.00057	CcSEcCtD
Epoprostenol—Headache—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—lymphatic system cancer	0.000538	0.000538	CcSEcCtD
